Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Botulinum Toxin Injection Efficacy in the Treatment of Head Essential Tremor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients suffering from a head tremor without (isolated) or with associated~* tremor in any other body parts.~* The HT must be troublesome for the patients (TRS 2 for the head tremor~* severity item).~* Patients never treated with botulinum toxin or not treated with botulinum toxin for this indication for at least 4 months.~* Men or women aged from 18 to 80 years old.~* Social security coverage.~* Ability to provide informed consent.~Exclusion Criteria:~* Patients with tremor from cerebellar syndrome (multiple sclerosis, etc.).~* Patients with a predominant dystonic jerky or myoclonic head tremor using~* the Tsui scale (\>1).~* Oral treatments for HT are allowed but must be stable during the study.~* Any contra-indication to Botulinum toxin.~* Women without efficient contraception.~* Patients under supervision or (legal) guardianship.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- EXPERIMENTAL GROUP (Type: EXPERIMENTAL): Patients eligible for inclusion will be randomized to one of the two groups:~* Experimental group: 60 patients will receive 2 injections of Btx A (BOTOX - Allergan), one on D0 and one at 12W (into each splenius capitis).~* Control group: 60 patients will receive 2 injections of placebo, one on D0 and one at 12W (into each splenius capitis).
- CONTROL GROUP (Type: OTHER): Patients eligible for inclusion will be randomized to one of the two groups:~* Experimental group: 60 patients will receive 2 injections of Btx A (BOTOX - Allergan), one on D0 and one at 12W (into each splenius capitis).~* Control group: 60 patients will receive 2 injections of placebo, one on D0 and one at 12W (into each splenius capitis).

Based on this trial design, predict the completion outcome and termination type (if applicable).